Clinical trials: Acute Leukemia (Category)
Acute Lymphoblastic Leukaemia - Category
CiproPAL (Ciprofloxacin Prophylaxis in Acute Leukaemia)
CiproPAL is a randomised trial comparing daily ciprofloxacin with local standard care during the induction phase of paediatric ALL treatment, and aims: 1.
- Trial name
- CiproPAL (NCT04678869)
- Testing
- Ciprofloxacin, Antibiotic
- Where
- 14 sites in United Kingdom
- Volunteers
- 313 people
- Sponsor
- University College, London
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL)
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant.
- Conditions
- AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome)
- Trial name
- ACCELERATE (NCT06859424)
- Testing
- Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C
- Where
- 13 sites in United States
- Volunteers
- 358 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) risk category is being determined.
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia
- Trial name
- NCT06289673
- Testing
- Dexamethasone, Vincristine, Daunorubicin
- Where
- 5 sites in United States
- Volunteers
- 850 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Myeloid Leukemia With Multilineage Dysplasia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells
Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
This phase I/II trial studies the side effects of glutaminase inhibitor CB-839 in combination with azacitidine in treating patients with myelodysplastic syndrome that has spread to other places in the body.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Blasts 20-30 Percent of Peripheral Blood White Cells, Chronic Myelomonocytic Leukemia
- Trial name
- NCT03047993
- Testing
- Azacitidine, Glutaminase Inhibitor CB-839
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Leukemia (Category)
First Report, Five Years Experience of the Acute Leukemia Work Group
The purpose of this study is to describe the incidence, clinic characteristics, biological and suvirval in Lymphoblastic Leukemia patients in Mexico City reference hospitals.
- Trial name
- PR-GTLA (NCT02990104)
- Where
- Mexico
- Volunteers
- 500 people
- Sponsor
- Mexican Agrupation for Hematology Study
Acute Leukemia (Category)
Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia
The main objective of this randomized trial is to compare disease-free survival (DFS) in high risk leukemia patients who underwent haploidentical HCT followed by an add back strategy of HSV-Tk donor lymphocytes or standard…
- Trial name
- TK008 (NCT00914628)
- Testing
- HSV-Tk, T-cell depleted or T-cell replete strategies
- Where
- 36 sites in United States, Belgium and 8 more
- Volunteers
- 92 people
- Sponsor
- AGC Biologics S.p.A.
Acute Lymphoblastic Leukaemia - Category
UNDERSTANDING THE T-CELL AND B-CELL RECEPTOR REPERTOIRE IN CHILDREN AND YOUNG ADULTS WITH ANTI-DRUG ANTIBODIES AGAINST PEG ASPARAGINASE
The aim of this sub study is to identify biomarkers in children and young adults with Acute Lymphoblastic Leukemia with hypersensitivity to PEG-asparaginase.
- Trial name
- NCT07499336
- Testing
- Hypersensitivity reaction to asparaginase
- Volunteers
- 45 people
- Sponsor
- Aarhus University Hospital